SV Konstantinides, G Meyer, C Becattini… - European heart …, 2020 - academic.oup.com
determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the …
N Galiè, M Humbert, JL Vachiery, S Gibbs… - European heart …, 2016 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and respiratory …
YM Ende-Verhaar, SC Cannegieter… - European …, 2017 - Eur Respiratory Soc
The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism (PE) is relevant for management decisions but is currently unknown. We …
G Simonneau, MA Gatzoulis, I Adatia… - Journal of the American …, 2013 - jacc.org
In 1998, a clinical classification of pulmonary hypertension (PH) was established, categorizing PH into groups which share similar pathological and hemodynamic …
NH Kim, M Delcroix, X Jais, MM Madani… - European …, 2019 - Eur Respiratory Soc
Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and a major cause of chronic PH leading to right heart failure and death. Lung …
Authors/Task Force Members… - European heart …, 2014 - academic.oup.com
The task of developing ESC Guidelines covers not only the integration of the most recent research, but also the creation of educational tools and implementation programmes for the …
HA Ghofrani, G Simonneau, AM D'Armini… - The Lancet …, 2024 - thelancet.com
Background Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension …
Background—Chronic thromboembolic pulmonary hypertension results from incomplete resolution of pulmonary emboli. Pulmonary endarterectomy (PEA) is potentially curative, but …